文献速递白血病

抑制非典型激酶WNK1作为TAL相关T细胞急性淋巴细胞白血病的治疗策略

Inhibition of the atypical kinase WNK1 as a therapeutic strategy in TAL-related T-cell acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2026-01-01

该研究通过磷酸化蛋白质组学与基因组学整合,将WNK1鉴定为T-ALL的潜在治疗靶点。功能缺失研究和WNK抑制剂在体外、体内模型及临床样本中验证:抑制WNK1可诱导多倍体、细胞增殖停滞及有丝分裂缺陷。WNK1在TAL1/2相关亚组中过表达,而在正常胸腺或淋巴结中不表达,提示其作为治疗靶点的转化潜力。

要点

  • WNK1在TAL1/2相关T-ALL亚组中过表达,正常胸腺和淋巴结不表达。
  • 抑制WNK1可诱导多倍体、增殖停滞及有丝分裂/胞质分裂缺陷。
  • WNK1非典型ATP结合口袋为开发高选择性小分子提供机会。

核心结论

  • WNK1是TAL相关T-ALL的潜在治疗靶点,抑制WNK1可诱导多倍体和增殖停滞。
  • WNK1在TAL1/2相关亚组中过表达,在正常胸腺或淋巴结中不表达。
  • WNK1的非典型ATP结合口袋为开发高选择性小分子提供独特机会。

研究设计与样本

  • 研究整合无偏磷酸化蛋白质组学与基因组学方法,将易损激酶列表与T-ALL细胞系磷酸化蛋白质组数据配对。
  • 通过功能缺失研究验证WNK1,并在多种体外和体内T-ALL模型及临床T-ALL样本中测试WNK抑制剂。

主要发现

  • 治疗性抑制WNK1促进多倍体,导致细胞增殖停滞和形态学改变,如细胞分裂不完全或染色体分离异常。
  • WNK1在TAL1/2相关亚组中过表达,但在正常胸腺或淋巴结中不表达。
  • WNK1在白血病建立和进展中具有功能贡献。

关键数值与推荐

  • WNK1是一种非典型丝氨酸/苏氨酸激酶,其亚结构域II缺乏保守赖氨酸,亚结构域I含有半胱氨酸,对ATP结合至关重要。

临床怎么用

  • 抑制WNK1可能为携带PTEN突变和del(6q)的预后不良T-ALL提供治疗策略。
  • WNK1非典型ATP结构域可用于开发高选择性小分子抑制剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Driver mutations in T-cell acute lymphoblastic leukemia (T-ALL) rarely affect druggable kinases. However, these kinases can be aberrantly activated or repressed as secondary oncogenic events. Thus, integrating unbiased phosphoproteomics with genomic approaches may offer novel opportunities for target discovery and therapeutic interventions. In our study, we identified WNK1 (with no lysine [K]) as a potential target in T-ALL by pairing a list of vulnerable kinases with data from a phosphoproteomic screen of T-ALL cell lines. We subsequently validated WNK1 by loss-of-function-based studies and tested WNK inhibitors in several in vitro and in vivo T-ALL models and clinical T-ALL samples. We showed that therapeutic WNK1 repression promotes polyploidy, resulting in cell proliferation arrest, and morphometric changes, such as incomplete cell division or chromosome segregation through altered mitotic spindle assembly and abscission defects. Furthermore, we found that WNK1 is overexpressed in the TAL1/2-related subgroup, but not in normal thymus or lymph nodes, suggesting a potential translational area for clinical exploitation in poor-prognosis T-ALL carrying PTEN mutations and del(6q). Our work also reports a functional contribution of WNK1 in the leukemia establishment and progression. Structurally WNK1 is an atypical serine/threonine kinase that diverges from canonical kinases by lacking the conserved lysine in subdomain II, instead featuring a cysteine in subdomain I, which is critical for adenosine triphosphate (ATP) binding. This unusual structural configuration creates a distinct ATP-binding pocket with limited sequence similarity to conventional kinases, offering a unique opportunity to develop highly selective small molecules. Targeting this atypical ATP domain could thus provide a therapeutic advantage and broaden the treatment landscape for T-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Montanaro A, Monica G, Zamponi R, et al. Inhibition of the atypical kinase WNK1 as a therapeutic strategy in TAL-related T-cell acute lymphoblastic leukemia. Blood. 2026. PMID: 42154791. doi:10.1182/blood.2025029901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。